It was a spectacular day for shareholders of another drug maker, MannKind. Shares surged an astounding 74 percent after an FDA panel recommended the approval of its experimental diabetes drug which you inhale, which means more needles to get insulin. Sheila Dharmarajan has more on the hopes for this new drug and what it will take before it hits the market.
Hot Topics
-
Hosts
About NBR
“Nightly Business Report produced by CNBC” (NBR) is an award-winning and highly-respected nightly business news program that airs on public television. Television’s longest-running evening business news broadcast, “NBR” features in-depth coverage and analysis of the biggest financial news stories of the day and access to some of the world’s top business leaders and policy makers.Top Stories from CNBC
- Bitcoin tumbles below $30,000, extending its plunge to start 2021
- 'No Time to Die,' 'Ghostbusters: Afterlife,' 'Uncharted' among latest Hollywood film delays
- Alphabet cancels Loon, project to beam internet to earth from balloons
- Johnson & Johnson plans to have 100 million vaccines for Americans by spring, board member says
- Biden is already facing pressure to scale back his $1.9 trillion Covid relief plan
NBR on Twitter
My TweetsNBR on Facebook
Subscribe to RSS